Beilu Pharma(SZ:300016)2025-01-24 09:06Revenue and Profit Projections - The company expects operating revenue for 2024 to be between CNY 950 million and CNY 1.05 billion, representing a year-on-year increase of 6.66% to 17.88% compared to CNY 890.72 million in the previous year[4]. - The net profit attributable to shareholders is projected to be between CNY 9.5 million and CNY 12.5 million, a significant recovery from a loss of CNY 71.76 million in the previous year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is also expected to be between CNY 9.5 million and CNY 12.5 million, compared to a loss of CNY 69.55 million last year[4]. Factors Contributing to Profitability - The company achieved a turnaround in net profit due to effective marketing reforms and stable growth in its chemical drug segment, alongside the acquisition of 80% equity in Tianyuan Pharmaceutical[7]. - The overall revenue growth is supported by the stable performance of the chemical drug segment and the growth of the traditional Chinese medicine segment following the acquisition[7]. - The company has streamlined processes and improved operational efficiency, leading to better management of period expenses[7]. Research and Development - Research and development investment remains at a high level, although it has decreased compared to the previous year[7]. Goodwill and Non-recurring Items - There was no goodwill impairment recorded in the current period, contrasting with a goodwill impairment of CNY 31.82 million from the acquisition of Zhejiang Haichang Pharmaceutical last year[7]. - Non-recurring gains and losses are expected to have a minimal impact of approximately CNY 151,700 on the net profit attributable to shareholders[7]. Information Disclosure - The detailed financial data for 2024 will be disclosed in the company's annual report, with a commitment to timely information disclosure[8].